Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer.

摘要: With the introduction of anthracycline-based regimens, 5-year survival rates have significantly improved in patients with early-stage breast cancer. addition trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor-2 (HER2), improvements overall been observed among advanced HER2-positive disease. Subsequently, lapatinib, an orally bioavailable small molecule dual HER2- and EGFR/HER1-specific tyrosine kinase inhibitor, received Food Drug Administration (FDA) approval combination capecitabine for HER2+ Then, pertuzumab 2012 ado-trastuzumab emtansine 2013 were approved US elsewhere based on evidence showing improvement outcomes mostly trastuzumab naive or trastuzumab-exposed metastatic The FDA also 1 year extended adjuvant neratinib after chemotherapy cancer basis ExteNET trial. clinical benefit demonstrated by those drugs disease has triggered several neoadjuvant trials testing them chemotherapy, but without conventional using single HER2-targeting drugs. In this article, we review current data therapeutic management setting. We efficacy safety nonanthracycline-based regimens combined optimum tumors.